Hostname: page-component-848d4c4894-r5zm4 Total loading time: 0 Render date: 2024-06-30T20:25:02.382Z Has data issue: false hasContentIssue false

Risk Factors Associated With the Acquisition of Amikacin-Resistant Gram-Negative Bacilli in Central New Jersey Hospitals

Published online by Cambridge University Press:  02 January 2015

Abstract

A case-control study was performed in central New Jersey hospitals to evaluate the potential patient factors associated with the acquisition of amikacin-resistant gram-negative bacilli (ARGNB).

Univariate analysis revealed an association between numerous patient factors, and multivariate analysis revealed four factors to be associated independently with ARGNB: the number of hospital admissions during the prior year, previous aminoglycoside exposure, intubation, and intensive–care–unit admission

Type
Concise Communications
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. New Jersey Department of Health, Division of Epidemiology, Environmental and Occupational Health Services, Epidemiology Surveillance System 1992 Annual Report. Trenton, NJ: NJDH; 1993.Google Scholar
2. Cross, AS, Opal, S, Kopecko, DJ. Progressive increase in the antibiotic resistance of gram-negative bacterial isolates. Walter Reed Hospital, 1976 to 1980: specific analysis of gentamicin, tobramycin, and amikacin resistance. Arch Intern Med 1983;143:2075ߝ2080.CrossRefGoogle ScholarPubMed
3. Hesseling, PB, Mouton, WL, Henning, PA, Kirsten, GF, Spruyt, LL, Schraader, EB, et al. A prospective study of long-term use of amikacin in a pediatrics department. Indications, administration, sidoeffects, bacterial isolates and resistance. S Afr Med J 1990;78:192ߝ195.Google Scholar
4. King, JW, White, MC, Todd, JR, Conrad, SA. Alterations in the microbial flora and in the incidence of bacteremia at a university hospital after adoption of amikacin as the sole formulary aminoglycoside. Clin Infect Dis 1992;14:908ߝ915.CrossRefGoogle Scholar
5. Gerding, DN, Larson, TA. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Am J Med 1985;79(suppl 1A):1ߝ7.CrossRefGoogle ScholarPubMed
6. Friedland, IR, Funk, E, Khoosal, M, Klugman, KP. Increased resistance to amikacin in a neonatal unit following intensive amikacin use. Antimicrob Agents Chemother 1992;36:1596ߝ1600.CrossRefGoogle Scholar
7. Ruiz-Palacios, GM, Ponce de Leon, S, Sifuentes, J, Ponce de Leon, J, Calva, JJ, Huazano, F, et al. Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin. Am J Med 1986;80(6B):71ߝ75.CrossRefGoogle ScholarPubMed
8. Saavedra, S, Vera, D, Ramierez-Ronda, CH. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line therapy. Am J Med 1986;80:65ߝ70.CrossRefGoogle Scholar
9. Chow, JW, Fine, MJ, Shlaes, DM, Quinn, JP, Hooper, DC. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585ߝ590.CrossRefGoogle ScholarPubMed
10. Gaynes, R. Antibiotic resistance in ICUs: a multifaceted problem requiring a multifaceted solution. Infect Control Hosp Epidemiol 1995;16:328ߝ330.CrossRefGoogle ScholarPubMed
11. Bryce, EA, Smith, JA. Focused microbiological surveillance and gram-negative p-lactamase-mediated resistance in an intensive-care unit. Infect Control Hosp Epidemiol 1995;16:331ߝ334.CrossRefGoogle Scholar
12. Dunagan, WC, Woodward, RS, Medoff, G, Gray, JL, Casabar, E, Lawrenz, C, et al. Antibiotic misuse in two clinical situations: positive blood cultures and administration of antibiotics. Rev Infect Dis 1991;13:405ߝ412.CrossRefGoogle Scholar